Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

What was studied

This study tested a new drug called iza-bren in small cell lung cancer. In all people, the cancer had spread widely. All 52 people had cancer that grew again after earlier care. It was an early trial with no other group to compare with. Everyone knew which drug they got. Each cycle lasted 3 weeks. People got the drug on day 1 and day 8. The team looked at tumor shrinking and at side effects.

What they found

Tumors shrank in part of the group. The middle time before the cancer grew was 4.1 months. The middle survival time was 12.2 months. For 22 people, this drug was their second line of care. In them, tumors shrank more often. Their middle time before growth was 6.2 months. Their middle survival time was 15.0 months. The main side effects were low blood cell counts. An early look hinted that tumors with HER3 may respond more.

What it means for patients

The authors say the drug showed good signs against this cancer. This was in people whose cancer came back. The signs looked strongest when it was the second line of care. A later-stage trial now tests it against topotecan. That trial puts people into groups by chance.

Why it is not certain yet

The study had only 52 people. There was no other group to compare with. So it is hard to judge the true effect. Everyone knew which drug they got. The second-line group had just 22 people. The HER3 link came from an early side look and is not firm. The later trial is still going on.

Source

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.